16.	Related Party Transactions

Roche Holdings, Inc. and its affiliates

Related-party molecular information services revenue from Roche for the three months ended June 30, 2017 and 2016 was $5,520,000 and $5,682,000, respectively, and $11,024,000 and $11,236,000 for the six months ended June 30, 2017 and 2016, respectively, which was earned under the Molecular Information Platform Program and ex-U.S. Commercialization Agreement.

Related-party pharma research and development services revenue from Roche for the three months ended June 30, 2017 and 2016 was $3,492,000 and $1,843,000, respectively, and $7,635,000 and $9,244,000 for the six months ended June 30, 2017 and 2016, respectively, from the reimbursement of R&D costs under the CDx Development, Immunotherapy Testing Platform Development and other programs.

Costs of related-party molecular information services from Roche were $2,045,000 and $471,000 for the three months ended June 30, 2017 and 2016, respectively, and $2,945,000 and $1,833,000 for six months ended June 30, 2017 and 2016, respectively, which consisted of costs incurred under the Molecular Information Platform Program and costs related to the delivery of services outside of the United States under the Ex-U.S. Commercialization Agreement.

At June 30, 2017, $4,082,000 and $3,742,000 was included in total accounts receivable and deferred revenue, respectively, related to this arrangement. At December 31, 2016, $2,007,000 and $3,747,000 was included in total accounts receivable and deferred revenue, respectively, related to this arrangement. There were no other material Roche-related balances included in the condensed consolidated financial statements as of June 30, 2017 or December 31, 2016, or for the three and six months ended June 30, 2017 and 2016.

Other related party transactions

The Company recognized revenue of $64,000 and $149,000 for the three and six months ended June 30, 2017, respectively, and $1,121,000 and $1,152,000 during the three and six months ended June 30, 2016, respectively, from an arrangement with an entity affiliated with a former member of the Company’s Board executed during the year ended December 31, 2013. At June 30, 2017 and December 31, 2016, there was $149,000 and $0, respectively, included in accounts receivable related to this arrangement.